MetaVia shares hit as Phase 1 data for DA-1726 drug looks promising
MetaVia reported positive interim data from its Phase 1 Part 3B study of DA-1726, demonstrating significant reductions in liver fat. The company announced plans for a Phase 2 trial and the appointment of a new Chief Medical Officer.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed